Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.
Vaccine
; 36(12): 1537-1541, 2018 03 14.
Article
em En
| MEDLINE
| ID: mdl-29463421
ABSTRACT
BACKGROUND:
An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70â¯years (ZOE-50 and ZOE-70, respectively).METHODS:
Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.RESULTS:
In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5-99.9%) in adults aged ≥50â¯years and 91.6% (43.3-99.8%) in adults ≥70â¯years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported.CONCLUSIONS:
HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229).Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vacinas
/
Herpes Zoster
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article